The Effect of Sodium Channel Blocker, Mexiletine, on Body Weight in Type 2 Diabetes Patients with Visceral Obesity

Objective: Mexiletine is an anti-arrhythmic agent also used for the treatment of painful diabetic neuropathy. In this study, the effect of mexiletine on body weight was evaluated in type 2 diabetes patients with diabetic neuropathy exhibiting visceral obesity. Methods: Type 2 diabetes patients with neuropathy exhibiting visceral obesity (n = 21) treated by mexiletine (300 mg/day) and a control group of type 2 diabetes patients with the same condition who received vitamin B12 (n = 12) were retrospectively evaluated. Body weight, waist circumference, hemoglobin A1c (HbA1c), blood pressure, liver function, serum lipids, and serum uric acid were assessed before and 6 months after the treatment. Results: Mexiletine significantly decreased body weight and waist circumference. The changes in body weight and waist circumference in 6 months in the mexiletine group were greater than in the control group. In metabolic parameters, there were significant decreases in triglyceride (TG) and serum uric acid. There were positive relationships between the change in body weight and the changes in TG, uric acid, alanine aminotransferase (ALT), and HbA1c. Conclusions: Mexiletine may affect body weight regulation. It ameliorated the metabolic parameters possibly by decreasing visceral fat. Further study should be performed to clarify the mechanism of the effect.

• Publication year

  2019

• Venue

  Clinical Medicine Insights: Endocrinology and Diabetes

• Publication date

  2019-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1179551418825049PMID 30733634PMCID 6343451
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of tetrodotoxin application and lidocaine supplementation on equine jejunal smooth muscle contractility and activity of the enteric nervous system in vitro.

  2014cited by this paper
• Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality.

  2013cited by this paper
• Mexiletine

  2012cited by this paper
• Visceral adiposity as a target for the management of the metabolic syndrome

  2012cited by this paper
• Non‐peristaltic patterns of motor activity in the guinea‐pig proximal colon

  2010cited by this paper
• ICC‐MY coordinate smooth muscle electrical and mechanical activity in the murine small intestine

  2010cited by this paper
• A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.

  2009cited by this paper
• Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk.

  2008cited by this paper
• Is visceral obesity the cause of the metabolic syndrome?

  2006cited by this paper
• Interstitial cells of cajal as pacemakers in the gastrointestinal tract.

  2006cited by this paper
• Increased visceral fat and impaired glucose tolerance predict the increased risk of metabolic syndrome in Japanese middle-aged men.

  2005cited by this paper
• Metabolic syndrome--definition and diagnostic criteria in Japan.

  2005cited by this paper
• Sodium current in human intestinal interstitial cells of Cajal.

  2003cited by this paper
• Sodium current in human jejunal circular smooth muscle cells.

  2002cited by this paper
• Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel?

  1996cited by this paper
• Pathophysiology and pathogenesis of visceral fat obesity.

  1995cited by this paper
• Pathophysiology and pathogenesis of visceral fat obesity.

  1994cited by this paper
• Mexiletine in the Treatment of Diabetic Neuropathy

  1992cited by this paper
• Effects of methylcobalamin on diabetic neuropathy.

  1992cited by this paper
• Erratum to A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in the Treatment of Arrhythmias

  1991cited by this paper
• Sodium channel blockers alter slow-wave frequency of the rat stomach in vivo.

  1991cited by this paper
• Mexiletine: Pharmacology and therapeutic use

  1990cited by this paper
• Mexiletine: Long-term Efficacy and Side Effects in Patients With Chronic Drug-Resistant Potentially Lethal Ventricular Arrhythmias

  1990cited by this paper
• Mexiletine for treatment of chronic painful diabetic neuropathy.

  1988cited by this paper

• Effect of Obesity on the Use of Antiarrhythmics in Adults With Atrial Fibrillation: A Narrative Review

  2024cites this paper
• Evaluation of Vibrational, Electronic, Topology, Reactivity, Bioactivity, Bioavailability and Blood-Brain Barrier Score of 1-(2,6-dimethylphenoxy)propan-2-amine-A DFT, Spectro-scopic and Molecular Docking Approach

  2022cites this paper
• A Low‐Frequency Pulsed Magnetic Field Reduces Neuropathic Pain by Regulating NaV1.8 and NaV1.9 Sodium Channels at the Transcriptional Level in Diabetic Rats

  2021cites this paper